Latest News and Updates | Cantargia

* (R) = Regulatory press releases

Mar 1, 2022

(R) Cantargia reports positive preclinical efficacy data for CAN10 demonstrating anti-fibrotic and anti-inflammatory effects in systemic sclerosis

Feb 24, 2022

(R) Cantargia publishes full year report for 2021

Feb 22, 2022

(R) Cantargia reports encouraging new CAN10 toxicology results and schedules phase I trial for 2023

Feb 8, 2022

Invitation to presentation of Cantargia’s report for the fourth quarter of 2021 on February 24 at 3.00 p.m. CET

Feb 4, 2022

(R) Cantargia reports treatment of first non-squamous non-small cell lung cancer patient in new arm of CANFOUR study

Feb 3, 2022

(R) Cantargia reports positive safety data from CIRIFOUR clinical study on nadunolimab and pembrolizumab combination

Jan 19, 2022

(R) Cantargia reports third party appeal against EPO decision in favor of Cantargia patent

Jan 14, 2022

(R) Cantargia reports treatment of first triple negative breast cancer patient in TRIFOUR study

Jan 3, 2022

(R) Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precision Promise[SM] phase 2/3 clinical trial

Dec 29, 2021

(R) Cantargia reports updated encouraging survival data from CANFOUR trial with nadunolimab and chemotherapy in pancreatic cancer

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye